More efforts to decipher the regulation of HIF-1 signalling in diabetes may provide novel and more specific therapeutic targets as well as efficient biomarkers for the identification of individuals who are most likely to benefit from HIF-targeting therapy. This evidence concerns the gene HIF1A and diabetes mellitus.